Netarsudil is a rho kinase inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops for ophthalmic and topical use. MedsAcross supplies Netarsudil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. RHOPRESSA ® is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Source: US FDA prescribing information
Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown.
Source: US FDA prescribing information
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart. One drop into the affected eye(s) once daily in the evening.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Epithelial Corneal Edema Epithelial corneal edema, described as honeycomb or bullous, has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures that could affect corneal endothelial function. Epithelial corneal edema typically resolves upon discontinuation of RHOPRESSA. Advise patients to notify their physician if they experience eye pain or decreased vision while using RHOPRESSA.
Source: US FDA prescribing information
The most common adverse reaction is conjunctival hyperemia (53%). Other common adverse reactions, approximately 20% include: corneal verticillata, instillation site pain, and conjunctival hemorrhage.
Source: US FDA prescribing information
Store at 2°C to 8°C (36°F to 46°F) until opened. During shipment, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days. After opening, the product may be kept at 2°C to 25°C (36°F to 77°F) for up to 6 weeks. If after opening the product is kept refrigerated at 2°C to 8°C (36°F to 46°F), then the product can be used until the expiration date stamped on the bottle.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Netarsudil, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Rhopressa 0.2 mg/mL eye dropsOphthalmic, topical Cold chain | Alcon Laboratories | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Netarsudil and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Netarsudil, including Rhopressa.
Yes. The US FDA first approved Netarsudil on 18 December 2017, according to Drugs@FDA.
Yes. Netarsudil has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Netarsudil must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Netarsudil is classified under ATC code S01EX05 (Netarsudil).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.